Log in
Enquire now
Mekonos

Mekonos

Mekonos is a company that creates cell-engineering platforms

OverviewStructured DataIssuesContributors

Contents

mekonos.com
Is a
Company
Company
Organization
Organization

Company attributes

Industry
Regenerative medicine
Regenerative medicine
Technology
Technology
Drug development
Drug development
Therapeutics
Therapeutics
Drug discovery
Drug discovery
Biomanufacturing
Biomanufacturing
Engineering
Engineering
Biotechnology
Biotechnology
...
Location
San Francisco
San Francisco
CEO
Anil Narasimha
Anil Narasimha
Founder
Anil Narasimha
Anil Narasimha
Steven Banerjee
Steven Banerjee
AngelList URL
angel.co/mekonos
Legal Name
Mekonos Inc.
Number of Employees (Ranges)
1 – 10
Full Address
44 MONTGOMERY STREET, SUITE 300 SAN FRANCISCO, CA 94104
CIK Number
1,838,228
Investors
Reimagined Ventures
Reimagined Ventures
Novartis
Novartis
Elementum Ventures
Elementum Ventures
dRx Capital
dRx Capital
0
Section 32 (venture capital firm)
Section 32 (venture capital firm)
Sands Capital Ventures
Sands Capital Ventures
TDK Ventures
TDK Ventures
‌
Fiscus Ventures
DUNS Number
12244793
Founded Date
May 2017
Total Funding Amount (USD)
31,000,000
Latest Funding Round Date
November 10, 2021
Latest Funding Type
Series A
Series A
Patents Assigned (Count)
1
Wellfound ID
mekonos
Country
United States
United States

Other attributes

Company Operating Status
Active
Latest Funding Round Amount (USD)
25,000,000

Mekonos is a company that has created a platform that allows cell and gene therapies to be more accessible. The company was founded by Anil Narsimha, Greg Sitters, and Steven Banerjee in 2017, in San Francisco, California, United States.

Mekonos is responsible for developing over nine hundred therapeutic candidates, and expect roughly forty of them to be approved by the end of 2022. They developed their therapeutics through their platform solution, Iris, which is a System-on-a-Chip that allows for automated deliveries and precision for multiplexing.

Iris is a pharmaceutical and biotechnological platform that allows for targeted delivery and dose control of gene therapeutics that includes nucleic acids, protein complexes, and small molecules, and cell treatments such as primary, immune, and stem cells.

Microfluidics, micro-electro-mechanical systems, and chemistry to expand their catalogue of payloads and cell types. Their various methods of expansion allows Mekonos to scale their silicon technology for drug discover and development.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Mekonos

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.